Leading Pharma Companies and Regulators to Convene at 10th Annual Adaptive Clinical Trials Conference
核心洞察
Industry leaders from AstraZeneca, Novartis, and Roche will gather in London to discuss innovations in adaptive clinical trial designs and digital technology integration in drug development.
The conference will feature key regulatory perspectives from EMA and MHRA representatives, focusing on critical topics including umbrella trials and basket trial assessments.
Sessions will explore the application of adaptive designs in developing personalized medicines and the impact of digital technology on modern clinical trials.
The pharmaceutical industry's leading experts will convene in London on April 9-10, 2018, for the 10th annual Adaptive Designs in Clinical Trials conference, showcasing the latest innovations in clinical trial methodology and regulatory developments.
Digital Innovation and Trial Design Evolution
The conference arrives at a pivotal moment as the pharmaceutical industry undergoes digital transformation, with increasing focus on smartphone apps and digital devices revolutionizing trial execution. These technological advances are reshaping how researchers collect and analyze data, potentially leading to more efficient and patient-centric trial designs.
Expert Insights from Industry Leaders
An impressive roster of speakers from major pharmaceutical companies will share their expertise and experiences. James Matcham, Head of Biometrics for Early Clinical Development at AstraZeneca, joins Alex Sverdlov, Director and Statistical Scientist from Novartis, among other industry veterans, to provide insights into cutting-edge adaptive trial methodologies.
The regulatory perspective will be particularly robust, with Olivier Collignon from the European Medicines Agency (搜索) (EMA) and Beatrice Panico from the Medicines and Healthcare products Regulatory Agency (MHRA) offering guidance on regulatory considerations and compliance.
Advanced Trial Methodologies
The conference will delve into sophisticated trial designs, including:
- Platform trials and self-adapting priors
- Enrichment designs and group sequential trials
- Umbrella and basket trial planning and assessment
- Applications in personalized medicine development
Personalized Medicine and Targeted Therapies
A significant portion of the program will focus on how adaptive trial designs are advancing the development of personalized medicines and targeted therapies. This reflects the industry's movement toward more precise, patient-specific treatment approaches.
Industry Challenges and Opportunities
Participants will explore both the promises and challenges of implementing digital technology in clinical trials, with case studies demonstrating successful applications and lessons learned. The conference will provide a platform for addressing current industry challenges while highlighting opportunities for innovation in trial design.
The gathering represents a crucial opportunity for biostatisticians, clinical researchers, and regulatory experts to share knowledge and shape the future of clinical trial methodology. Early registration discounts are available, with savings of up to £400 for early registrants.